PTGS2 and pulmonary arterial hypertension: We now show that the COX-2 inhibitor SC-58125 [30] affected the eicosanoid metabolite profile differently in the lungs from the SuHx pulmonary animals when compared to the right ventricle (RV) tissue samples and surprisingly that chronic COX-2 inhibition did not worsen the PAH in this model.